Alpha-1 Adrenergic Receptor Blockers for the Treatment of Lower Urinary Tract Symptoms in Women: A Systematic Review and Meta-Analysis

키워드

참고문헌 (35)

1. Oelke M, "EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction", Eur Urol, 64, pp.118~140 (2013)
2. Haylen BT, "An International Urogynecological Association(IUGA)", International Continence Society(ICS)joint terminology and classification of the complications related directly to the insertion of prostheses(meshes, implants, tapes)and grafts in female pelvic floor surgery, 2011, pp.30, 2~12
3. Haylen BT, "Has the true prevalence of voiding difficulty in urogynecology patients been underestimated?", Int Urogynecol J Pelvic Floor Dysfunct, 18, pp.53~56 (2007)
4. Patel R, "Bladder outlet obstruction in women : prevalence, recognition, and management", Curr Urol Rep, 2, pp.379~387 (2001)
5. 이영숙, "Efficacy of an Alpha-Blocker for the Treatment of Nonneurogenic Voiding Dysfunction in Women: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial", International Neurourology Journal, 22(1), pp.30~40 (2018), 대한배뇨장애요실금학회
6. Pummangura N, "Efficacy of tamsulosin in the treatment of lower urinary tract symptoms(LUTS)in women", Asian J Surg, 30, pp.131~137 (2007)
7. Groutz A, "Non-neurogenic female voiding dysfunction", Curr Opin Urol, 12, pp.311~316 (2002)
8. 김재헌, "Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study", Yonsei Medical Journal, 57(2), pp.407~418 (2016), 연세대학교의과대학[DOI]
9. Moher D, "Preferred reporting items for systematic review and metaanalysis protocols(PRISMA-P)2015 statement", Syst Rev, 4, pp.1~ (2015)
10. Liberati A, "The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions : explanation and elaboration", PLoS Med, 6, pp.e1000100~ (2009)
11. Higgins JP, "The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials", BMJ, 343, pp.d5928~ (2011)
12. Downs SH, "The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions", J Epidemiol Community Health, 52, pp.377~384 (1998)
13. Luo D, "Optimally estimating the sample mean from the sample size, median, mid-range, and", or mid-quartile range, 2018, pp.27, 1785~1805
14. Wan X, "Estimating the sample mean and standard deviation from the sample size, median, range and", or interquartile range, 2014, pp.14, 135~
15. DerSimonian R, "Random-effects model for meta-analysis of clinical trials : an update", Contemp Clin Trials, 28, pp.105~114 (2007)
16. Athanasopoulos A, "Effect of alfuzosin on female primary bladder neck obstruction", Int Urogynecol J Pelvic Floor Dysfunct, 20, pp.217~222 (2009)
17. 장혁수, "하부요로증상을 가진 여성 환자에서 Tamsulosin 0.2mg 단독요법의 유효성", International Neurourology Journal, 10(2), pp.140~146 (2006), 대한배뇨장애요실금학회
18. Chang SJ, "The effectiveness of tamsulosin in treating women with voiding difficulty", Int J Urol, 15, pp.981~985 (2008)
19. Costantini E, "Open-label, longitudinal study of tamsulosin for functional bladder outlet obstruction in women", Urol Int, 83, pp.311~315 (2009)
20. Hajebrahimi S, "Effect of tamsulosin versus prazosin on clinical and urodynamic parameters in women with voiding difficulty : a randomized clinical trial", Int J Gen Med, 4, pp.35~39 (2011)
21. Kim SO, "The α1 adrenoceptor antagonist tamsulosin for the treatment of voiding symptoms improves nocturia and sleep quality in women", Urol J, 11, pp.1636~1641 (2014)
22. Kim SO, "Efficacy and safety of combined therapy with tamsulosin and tolterodine in female patients with a maximal flow rate less than 12 ml", s, 2011, pp.22, 1287~1291
23. Koh JS, "Comparison of alpha-blocker, extracorporeal magnetic stimulation alone and in combination in the management of female bladder outlet obstruction", Int Urogynecol J, 22, pp.849~854 (2011)
24. 이규성, "Efficacy and Safety of Tamsulosin for the Treatment of Non-neurogenic Voiding Dysfunction in Females: A 8-Week Prospective Study", Journal of Korean Medical Science, 25(1), pp.117~122 (2010), 대한의학회
25. Lepor H, "Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatismlike symptoms", J Urol, 154, pp.116~118 (1995)
26. Low BY, "Terazosin therapy for patients with female lower urinary tract symptoms : a randomized, double-blind, placebo controlled trial", J Urol, 179, pp.1461~1469 (2008)
27. Pischedda A, "Use of alpha1-blockers in female functional bladder neck obstruction", Urol Int, 74, pp.256~261 (2005)
28. Coyne KS, "The prevalence of lower urinary tract symptoms(LUTS)in the USA, the UK and Sweden : results from the Epidemiology of LUTS(EpiLUTS)study", BJU Int, 104, pp.352~360 (2009)
29. Kumar A, "Management of functional bladder neck obstruction in women : use of alpha-blockers and pediatric resectoscope for bladder neck incision", J Urol, 162, pp.2061~2065 (1999)
30. Yamanishi T, "Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor", Int J Urol, 11, pp.88~96 (2004)
31. Zhang HL, "Tamsulosin for treatment of lower urinary tract symptoms in women : a systematic review and meta-analysis", Int J Impot Res, 29, pp.148~156 (2017)
32. Abrams P, "Managing lower urinary tract symptoms in older men", BMJ, 310, pp.1113~1117 (1995)
33. van Leeuwen JH, "The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms", Eur Urol, 50, pp.440~452 (2006)
34. Nickel JC, "Placebo therapy of benign prostatic hyperplasia : a 25-month study", J Urol, 160, pp.1584~1585 (1998)
35. Hauptman J, "Orlistat in the long-term treatment of obesity in primary care settings", Arch Fam Med, 9, pp.160~167 (2000)

관련 논문AI추천